Wire · operational-macro
FDA approval, immunology pivot, and $105M financing extend cash runway into 2029
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 August 2026 · Fusion42 review
Spero Therapeutics received FDA approval for Utebzi, enabling a strategic shift to immunology with in-licensing of SP001 and $105M in non-dilutive financing, extending its cash runway through 2029. A phase II trial for SP001 in IgG4-related disease is planned in 2027.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
FDA approval opens a clear regulatory route for your immunology drug development, while fresh capital removes immediate funding risks. You can push trial timelines aggressively and reposition your pipeline around immune-mediated diseases now.
◆ Coverage
1 source · 12 Aug 2026
◆ Related on Wire
◆ Topics